Tradestie Institutional Equity Comparison Engine
EVMN vs DBVT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EVMN Overall Edge
EVMN Captures Institutional Edge (2โ1 Pillars ยท 3โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Evommune, Inc. (EVMN) driven by superior Growth & Margin, Options & Structure while DBVT counters with relative strength in Momentum & Technical. Fundamentally, EVMN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus DBVT at N/M Forward P/E and -5577.0% operating margin (-42.9% YoY). In options structure, EVMN sits in SURGE (53rd %ile IV; Dealer Gamma Walls on Pro) against DBVT sits in SURGE (13th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
EVMN N/M vs DBVT N/M Fwd P/E
Growth & Margin Winner
EVMN
Op Margin 0.0% vs -5577.0% ยท YoY +0.0% vs -42.9%
Momentum & Technical Winner
DBVT
1Y -61.0% vs -21.4% ยท 52W Pos 8% vs 9%
Options & Structure Winner
EVMN
SURGE (53rd %ile IV) vs SURGE (13th %ile IV)
EVMN
US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap
$315.5M
1M Return
+37.33%
1Y Return
-61.03%
Forward P/E
N/M
Unified AI Score
30.0 / 100
SELL
Tech 50.0
Fund 35.0
Flow 69.0
Mom 44.0
DBVT
NASDAQ
DBV Technologies S.A.
Biological Products, (No Disgnostic Substances)
$10.27
-6.76% 1D
Market Cap
$692.2M
1M Return
+13.48%
1Y Return
-21.36%
Forward P/E
N/M
Unified AI Score
30.9 / 100
SELL
Tech 15.0
Fund 36.0
Flow 60.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
EVMN -61.03%
DBVT -21.36%
Spread: +39.67 pp (DBVT Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | EVMN Revenue | DBVT Revenue | EVMN Op. Margin | DBVT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | N/A | $10M | N/A | -1162.8% | DBVT |
| FY2020 | N/A | $10M | N/A | -1408.7% | DBVT |
| FY2021 | N/A | $10M | N/A | -1727.6% | DBVT |
| FY2022 | N/A | $0M | N/A | -1994.9% | DBVT |
| FY2023 | N/A | $20M | N/A | -486.0% | DBVT |
| FY2024 | $10M | $0M | -1000.2% | -2808.7% | EVMN |
| FY2025 | $10M | $10M | -623.6% | -2609.2% | EVMN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EVMN | DBVT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $315.5M | $692.2M | Larger Scale | DBVT |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -42.9% | Higher Growth | EVMN |
| Operating Margin (TTM) Profitability | 0.0% | -5577.0% | Higher Margin | EVMN |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -69.5% | -205.8% | Higher ROE | EVMN |
| 52-Week Range Position Momentum | 8% ($5โ$33) | 9% ($9โ$26) | Stronger Trend | DBVT |
| Beta / 30D Volatility Risk Regime | 1.05ฮฒ ยท 118% Vol | 1.18ฮฒ ยท 77% Vol | Lower Realized Risk | DBVT |
| Unified Institutional Score Composite Signal | 30.0 / 100 (SELL) | 30.9 / 100 (SELL) | Higher Composite | DBVT |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full EVMN vs DBVT Buy Guide
EVMN
SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
53rd %ile
IV Regime
Balanced (25thโ60th %ile)
DBVT
SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
13th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither EVMN nor DBVT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.